| Changing patterns of mortality across Europe in patients infected with HIV-1 A Mocroft, S Vella, TL Benfield, A Chiesi, V Miller, P Gargalianos, ... The Lancet 352 (9142), 1725-1730, 1998 | 1672 | 1998 |
| Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy RS Hogg, B Yip, KJ Chan, E Wood, KJP Craib, MV O'Shaughnessy, ... Jama 286 (20), 2568-2577, 2001 | 1026 | 2001 |
| Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical … P Ljungman, M Boeckh, HH Hirsch, F Josephson, J Lundgren, G Nichols, ... Clin Infect Dis 64 (1), 87-91, 2017 | 969* | 2017 |
| Early brain invasion of iatrogenic human immunodeficiency virus infection. LS Davis, BL Hjelle, VE Miller, DL Palmer, AL Lewellyn, TL Merlin, ... Neurology, 1992 | 704 | 1992 |
| Hepatitis B cure: from discovery to regulatory approval AS Lok, F Zoulim, G Dusheiko, MG Ghany Hepatology 66 (4), 1296-1313, 2017 | 617 | 2017 |
| Advancing the global public health agenda for NAFLD: a consensus statement JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ... Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022 | 596 | 2022 |
| A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 … K Hertogs, MP de Béthune, V Miller, T Ivens, P Schel, ... Antimicrobial agents and chemotherapy 42 (2), 269-276, 1998 | 528 | 1998 |
| A global scientific strategy to cure hepatitis B PA Revill, FV Chisari, JM Block, M Dandri, AJ Gehring, H Guo, J Hu, ... The Lancet Gastroenterology & Hepatology 4 (7), 545-558, 2019 | 489 | 2019 |
| HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ... Aids 21 (2), 215-223, 2007 | 442 | 2007 |
| The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data … V DeGruttola, L Dix, R D'Aquila, D Holder, A Phillips, M Ait-Khaled, ... Antiviral therapy 5 (1), 41-48, 2000 | 420 | 2000 |
| HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load AN Phillips, S Staszewski, R Weber, O Kirk, P Francioli, V Miller, ... Jama 286 (20), 2560-2567, 2001 | 391 | 2001 |
| Hepatitis C virus drug resistance–associated substitutions: State of the art summary E Lontok, P Harrington, A Howe, T Kieffer, J Lennerstrand, O Lenz, ... Hepatology 62 (5), 1623-1632, 2015 | 351 | 2015 |
| Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy O Kirk, C Pedersen, A Cozzi-Lepri, F Antunes, V Miller, JM Gatell, ... Blood, The Journal of the American Society of Hematology 98 (12), 3406-3412, 2001 | 350 | 2001 |
| Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL‐AASLD HBV Treatment Endpoints Conference M Cornberg, ASF Lok, NA Terrault, F Zoulim, ... Hepatology 71 (3), 1070-1092, 2020 | 336 | 2020 |
| Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus J Lawrence, DL Mayers, KH Hullsiek, G Collins, DI Abrams, RB Reisler, ... New England Journal of Medicine 349 (9), 837-846, 2003 | 302 | 2003 |
| Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure V Miller, C Sabin, K Hertogs, S Bloor, J Martinez-Picado, R D'Aquila, ... Aids 14 (18), 2857-2867, 2000 | 284 | 2000 |
| Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples K Hertogs, S Bloor, SD Kemp, C Van den Eynde, TM Alcorn, R Pauwels, ... Aids 14 (9), 1203-1210, 2000 | 251 | 2000 |
| Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study V Miller, A Mocroft, P Reiss, C Katlama, AI Papadopoulos, T Katzenstein, ... Annals of internal medicine 130 (7), 570-577, 1999 | 232 | 1999 |
| Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis C Michailidis, AL Pozniak, S Mandalia, S Basnayake, MR Nelson, ... Antiviral therapy 10 (3), 417-422, 2005 | 216 | 2005 |
| Protein binding in antiretroviral therapies M Boffito, DJ Back, TF Blaschke, M Rowland, RJ Bertz, JG Gerber, V Miller AIDS research and human retroviruses 19 (9), 825-835, 2003 | 212 | 2003 |
